Dianthus (DNTH) Stock Jumps on Early CIDP Trial Success

Key Trial Milestone Achieved

Dianthus Therapeutics (NASDAQ:DNTH) shares surged over 25% following the announcement of an early 'GO' decision for its Phase 3 CAPTIVATE trial. The study evaluates claseprubart for treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a neurological disorder.

Positive Clinical Data Overview

The decision was reached after the trial achieved its primary endpoint ahead of schedule, with 20 confirmed responders from fewer than 40 participants. This outcome significantly exceeds the predefined target response rate of 50%. An independent Data Safety Monitoring Board reviewed the results and confirmed the positive safety profile, noting no related serious adverse events or discontinuations during the trial's initial phase.

Market Impact and Analyst Outlook

Following the news, Dianthus plans to engage with regulators to optimize the trial's next phase. The company also updated its development timeline, expecting top-line results for the trial's Part B by the end of 2026. The positive data prompted analyst upgrades, with Truist Securities raising its price target on DNTH to $110 from $63, and Guggenheim reiterating a Buy rating with a $200 price target, signaling strong confidence in the drug's potential.

Conclusion

The early trial success represents a significant de-risking event for Dianthus Therapeutics, bolstering investor confidence and positioning claseprubart as a promising candidate for CIDP treatment. Future catalysts include regulatory feedback and the progression of the trial's Part B.

FAQ

Q: Why did Dianthus Therapeutics stock increase sharply?
A: The stock rose after the company announced its drug claseprubart met its goals early in a Phase 3 clinical trial for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Q: What is the next major milestone for the CAPTIVATE trial?
A: Dianthus expects to provide top-line guidance for Part B of the CAPTIVATE trial by the end of 2026.

Source: Investing.com